Clinical Trial Update: Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes an intravesical delivery system delivering erdafitinib for localized, non-muscle-invasive bladder cancer, with Phase 1 and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Non-Muscle Invasive Bladder Neoplasms | Phase 1, Phase 2 | Status: RECRUITING